Edition:
United Kingdom

Ascendis Health Ltd (ASCJ.J)

ASCJ.J on Johannesburg Stock Exchange

339.00ZAc
14 Dec 2018
Change (% chg)

4.00 (+1.19%)
Prev Close
335.00
Open
340.00
Day's High
350.00
Day's Low
310.00
Volume
2,215,131
Avg. Vol
514,588
52-wk High
1,799.00
52-wk Low
307.00

Latest Key Developments (Source: Significant Developments)

Ascendis Health Identifies Pharma And Consumer Healthcare As Core Focus Areas
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Ascendis Health Ltd ::JSE: ASC - ASCENDIS HEALTH ADOPTS NEW STRATEGIC FOCUS.ASCENDIS HEALTH LTD - PHARMA AND CONSUMER HEALTHCARE HAVE BEEN IDENTIFIED BY GROUP AS CORE FOCUS AREAS.ASCENDIS HEALTH - PLANS TO DRIVE GEOGRAPHIC EXPANSION AND GROWTH BY STRENGTHENING ITS CURRENT FOOTHOLD IN EUROPE, MIDDLE EAST AND AFRICA.ASCENDIS HEALTH LTD - STRATEGIC NON-CORE BUSINESSES SHOULD BE DIVESTED TO ENSURE GREATER FOCUS ON CORE OPERATIONS.ASCENDIS HEALTH - BIOSCIENCES IDENTIFIED AS NON-CORE AND LOGICAL NEXT STEP IS FOR ASCENDIS HEALTH TO DIVEST FROM BUSINESS.ASCENDIS HEALTH LTD - CORE BUSINESSES WILL BE COMPLEMENTED BY TWO SOLID PERFORMING DIVISIONS, MEDICAL AND ANIMAL HEALTH.ASCENDIS HEALTH LTD - OPERATING MODEL WILL SHIFT FROM CURRENT GEOGRAPHIC STRUCTURE, FOCUSED ON SOUTH AFRICA AND EUROPE, TO A GLOBAL DIVISIONAL MODEL.ASCENDIS HEALTH LTD - GROUP'S TARGETED OBJECTIVE IS TO GENERATE A 7% TO 10% ORGANIC REVENUE GROWTH RATE BY 2023 FINANCIAL YEAR.ASCENDIS HEALTH - TARGETED OBJECTIVE IS TO GENERATE 22% TO 25% EBITDA MARGIN BY 2023 FINANCIAL YEAR.ASCENDIS HEALTH - FOUR ASSETS WHICH ARE EITHER NON-CORE TO LONGER-TERM STRATEGY OR NOT PERFORMING OPTIMALLY HAVE BEEN IDENTIFIED FOR DIVESTMENT.ASCENDIS HEALTH LTD - ASSETS IDENTIFIED FOR DIVESTMENT INCLUDE BIOSCIENCES BUSINESS.ASCENDIS HEALTH LTD - IN FINAL STAGES OF CONCLUDING A SALE AGREEMENT FOR ISANDO MANUFACTURING FACILITY.ASCENDIS HEALTH LTD - AGREEMENT HAS BEEN REACHED FOR SALE OF ASCENDIS DIRECT FOR R40 MILLION.  Full Article

Ascendis Health FY Normalised HEPS 159.7 Cents
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Ascendis Health Ltd ::FY REVENUE UP 21% TO R7.7 BILLION; FY NORMALISED HEPS UP 2% TO 159.7 CENTS.  Full Article

Ascendis Health Announces Update On Strategic Business Review And Change In Directors
Monday, 25 Jun 2018 

June 25 (Reuters) - Ascendis Health Ltd ::INVESTOR UPDATE ON STRATEGIC BUSINESS REVIEW AND CHANGE IN DIRECTORS.DURING INITIAL PHASE OF STRATEGIC REVIEW MANAGEMENT IDENTIFIED THREE ASSETS FOR DIVESTMENT.GROUP HAS DECIDED TO FOCUS SOLELY ON ITS BIGGEST SPORTS NUTRITION BRAND, SCITEC.PROCEEDS FROM DISPOSAL OF THESE ASSETS WILL BE REINVESTED IN BUSINESS TO FURTHER IMPROVE ORGANIC REVENUE GROWTH AND FINANCIAL RETURNS.NO LONGER PLANS TO OFFER ITS LOCAL PORTFOLIO OF FIVE SPORTS NUTRITION BRANDS IN SOUTH AFRICAN MARKET.HAS DECIDED TO DIVEST ASCENDIS SPORTS NUTRITION IN SOUTH AFRICA AND HAS INITIATED A SALE PROCESS TO DISPOSE OF BUSINESS.PLANNED FOR ASN TO BE SOLD AS A GOING CONCERN AND IT IS EXPECTED THAT ALL OF ITS STAFF WILL TRANSFER TO NEW OWNERS.CLIFF SAMPSON WILL BE RETIRING AS AN EXECUTIVE DIRECTOR AND MANAGING DIRECTOR OF GROUP'S SOUTH AFRICAN OPERATIONS ON 30 JUNE 2018.TO DISPOSE OF ASCENDIS DIRECT AS A GOING CONCERN AND HAS INVITED OFFERS FROM POTENTIAL BUYERS.DECIDED TO APPOINT AN INTERIM CHIEF OPERATING OFFICER TO LEAD SOUTH AFRICAN BUSINESS UNTIL STRATEGIC REVIEW PROCESS HAS BEEN COMPLETE.TO RETAIN GOOD MANUFACTURING PRACTICE APPROVED PHARMACEUTICAL MANUFACTURING FACILITY LOCATED IN WYNBERG, JOHANNESBURG, RATHER THAN ISANDO.APPOINTMENT OF MARNUS SONNEKUS AS INTERIM COO SOUTH AFRICA WITH EFFECT FROM 1 JULY 2018, BASED IN JOHANNESBURG.ASCENDIS HEALTH LTD - PLANS TO SELL ITS 23 000 M² GMP PHARMACEUTICAL MANUFACTURING FACILITY IN ISANDO.  Full Article

Ascendis Health announces acquisition of Kyron Laboratories Proprietary Ltd​
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ascendis Health Ltd ::‍ACQUISITION OF 100% OF KYRON LABORATORIES PROPRIETARY LIMITED​.DEAL ‍FOR A CONSIDERATION OF R396.4 MILLION UPFRONT PLUS A PERFORMANCE-BASED DEFERRED PORTION FROM NIXSIM PROPRIETARY LIMITED​.‍PURCHASE CONSIDERATION IS LIMITED TO A MAXIMUM OF R450 MILLION​.  Full Article

Ascendis Health says fully underwritten renounceable rights offer of 750 mln rand at 20.00 rand per share​
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Ascendis Health Ltd :‍BOARD HAS RESOLVED TO UNDERTAKE A FULLY UNDERWRITTEN RIGHTS OFFER TO RAISE APPROXIMATELY R750 MILLION TO FUND ACCELERATED PAYMENT.​.‍RIGHTS OFFER IS FULLY UNDERWRITTEN BY A WHOLLY OWNED SUBSIDIARY OF MAJOR SHAREHOLDER, COAST2COAST CAPITAL PROPRIETARY LIMITED​.FULLY UNDERWRITTEN RENOUNCEABLE RIGHTS OFFER OF 750 MILLION RAND AT 20.00 RAND PER SHARE​.  Full Article

Ascendis Health announces ‍transaction update relating to acquisition of Remedica​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ASCENDIS HEALTH LTD ::‍TRANSACTION UPDATE RELATING TO ASCENDIS' ACQUISITION OF REMEDICA​.‍BOARD HAS RESOLVED TO RAISE EQUITY TO REPAY PORTION OF CO'S MEDIUM TERM DEBT OBLIGATIONS IN ORDER TO REDUCE ITS DEBT POSITION​.‍BOARD ELECTED TO SETTLE A PORTION OF DEFERRED PAYMENT IN ADVANCE OF ITS DUE DATE​.  Full Article

Ascendis Health intends to raise about 750 mln rand in rights offering​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Ascendis Health Ltd :‍COMPANY INTENDS TO RAISE APPROXIMATELY 750 MILLION RAND IN RIGHTS OFFERING​.‍PROCEEDS WILL BE USED TO SETTLE A SIGNIFICANT PORTION OF OUTSTANDING DEFERRED VENDOR CONSIDERATION PAYMENTS​.‍ANTICIPATED THAT RIGHTS OFFER SHARES WILL BE OFFERED AT A PREMIUM TO CURRENT MARKET PRICE​.  Full Article

Ascendis says MD S.Africa operations to retire in June 2018
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - ASCENDIS HEALTH LTD ::‍CLIFF SAMPSON, MANAGING DIRECTOR OF ASCENDIS' SOUTH AFRICAN OPERATIONS, WILL REACH HIS RETIREMENT DATE ON 30 JUNE 2018​.‍SAMPSON HAS MADE HIMSELF AVAILABLE POST HIS RETIREMENT TO ENSURE A SMOOTH AND SUCCESSFUL HANDOVER​.‍BOARD IS IN PROCESS OF SECURING A REPLACEMENT EXECUTIVE​.  Full Article

Deals of the day-Mergers and acquisitions

June 25 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Monday: